Market Overview:
Migraine is a debilitating pain
disorder characterized by moderate to severe recurrent headaches. According to
the report that has been published by Market Research Future (MRFR), the global migraine market size is
anticipated to grow at a steady rate in the coming years.
Market Drivers and Restraints:
Migraine is one of the common
disorders that cause tender headaches and is generally associated with other
indications such as nausea, vomiting and sensitivity to light,
smell and sound. The occurrence of migraine is common in females
rather than males. Hence global increase in population,
especially female population has resulted in increased prevalence
of migraine leading to the high demand for effective treatments in the global
migraine industry.
The underlying mechanism of
migraine is not fully known. However, increasing incidences of migraine that is
triggered due to other causative disorders are fueling the growth of the global
migraine market. Absence of permanent cure for migraine and growing
genericization of drugs are creating multiple opportunities for pharmaceutical
companies to introduce effective medication and treatment for the condition,
leading to the growth of the global migraine market.
Changing lifestyles, increasing
stress levels and rise in prevalence of hormonal imbalance leading to migraine
are inducing high demand for proper medication in the global market, which in
turn is driving the global migraine market towards higher verticals. On the
flip side, over-reliance on over-the-counter painkillers and easy availability
of generics are likely to act as restraints on the growth of the global
migraine market.
Key
Players:
The leading players profiled by
MRFR in the report on the global migraine market are Allergan, Impax Laboratories,
Abbott Laboratories, Inc., Eisai Inc., Eli Lilly and Company, Pfizer, Inc.,
Johnson & Johnson, Klaria, Kowa Pharmaceuticals America, Luitpold
Pharmaceuticals, Meda, Merck, OptiNose, AstraZeneca plc, and GlaxoSmithKline
Plc.
Market Segmentation:
The global migraine market
research report has been segmented on the basis of types, treatment
types and drug class. Based on types, the migraine market is
segmented into episodic and chronic. Based on treatment types, the migraine
market is segmented into abortive and preventive. Based on drug class, the
migraine market is segmented into triptans, ergots and others.
Industry Updates:
In August
2018, University of Melbourne has launched a new course named
'Mastering migraine management' which highlights the latest advances in
migraine diagnosis and treatments for general practitioners. This course was
built in one year by a team of neurologists and is made available on any smart
device.
Regional Analysis:
Geographically, the global
migraine market is segmented into four major regions such as North America,
Europe, Asia Pacific and the Middle East and Africa. Increasing
healthcare expenditure, rise in prevalence of migraine and
availability of specialty migraine drugs are driving the migraine market in the
North America region. The growth of migraine market in the Asia
Pacific region is fueled by increasing investments by key players in the
emerging market in the developing economies of India and China. The migraine
market in the Europe region is projecting high growth potential owing to the
increasing demand for effective treatment for migraine in this region.
Ask Questions To The Experts @ https://www.marketresearchfuture.com/enquiry/2381
TABLE OF CONTENTS
1 Report Prologue
2 Introduction
2.1 Research Objective
2.2 Assumptions & Limitations
2.2.1 Assumptions
2.2.2 Limitations
2.3 Market Structure
3 Research Methodology
3.1 Primary Research
3.2 Secondary Research
…Continued!
Get full report & TOC @: https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=2381
